Financial year Results for the year ended 31.03.2025

Revenue declinedNet loss reportedEBITDA margin compressionExceptional itemNegative operating cash flowDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹29.12

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.5% vs market

Pharmaceuticals peers, median of 147sector-0.1%-0.3% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+0.1-0.5-0.1-0.3

Next day

-2.4-0.2-2.2-0.2-2.2

-1.7+0.3-2.0-0.2-1.5

+0.2+0.9-0.6+0.0+0.2

+2.2+0.8+1.5+0.0+2.2

+4.1+2.2+1.9+0.6+3.5

+4.7+3.4+1.4+1.4+3.3

15d

-3.5-0.8-2.7-2.9-0.6

+0.3+2.9-2.6+0.2+0.1

+3.2+0.8+2.4-0.5+3.7

-15.5+0.0-15.5-3.2-12.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

ANG Lifesciences reported a steep fall in revenues and widening losses for FY25. Standalone revenue from operations dropped to ₹8,991.01 lakhs from ₹13,136.88 lakhs a year ago (down ~31.5%), while consolidated revenue fell to ₹9,284.66 lakhs from ₹14,610.97 lakhs (down ~36.5%). Standalone net loss widened to ₹1,034.29 lakhs (vs ₹864.81 lakhs loss in FY24), and consolidated net loss deepened to ₹1,241.33 lakhs (vs ₹1,014.30 lakhs). Q4 also remained in the red, with standalone loss of ₹193.87 lakhs. The company booked exceptional items of ₹173.51 lakhs. Total borrowings rose to ₹6,780.33 lakhs (standalone), nearly matching total equity of ₹6,680.90 lakhs, and operating cash flow stayed negative at ₹(229.27) lakhs. Statutory auditor M/s Khurana Sharma & Co. issued an unmodified opinion.

Likely market impact

Negative for shareholders — shrinking top line, mounting losses, rising debt and weak cash generation point to sustained pressure on profitability. Stock may face downside sentiment unless the company demonstrates a credible turnaround.